For two years, Humana’s investment thesis rested on a single, unverified promise: that the company could claw back the four-star Medicare Advantage rating it lost in the 2024 star ratings (which set 2025 payments) and reclaim the federal bonus payments that go with it. On Thursday, October 8, 2026, CMS answered the question. Humana’s flagship H5216 contract climbed back to 4 stars from 3.5 stars in the 2027 Medicare Advantage star ratings, reinstating the company’s eligibility for federal quality bonus payments and setting the stage for a meaningful earnings uplift in 2028. Shares jumped roughly 13% after hours.
The question investors need to answer this morning is not whether the recovery is real. It is. The question is how much of the 2028 earnings recovery the market has already taken.
What Four Stars Is Actually Worth
The H5216 contract represents the most critical component of Humana’s long-term 2028 earnings target and is worth approximately $1.5 billion of EBIT and $9 of earnings per share, according to Barclays analyst Andrew Mok. That figure puts the stakes in concrete terms: this was not a minor quality scorecard adjustment. Humana has previously framed the Star Ratings decline as a multi-billion-dollar earnings headwind, and management has said its plan is to rebuild performance toward top-quartile results by the time 2028 bonus payments are determined.
The ratings published Thursday do not change this year’s results. They feed payments in 2028, which is why a single half-star move on a large contract can be worth hundreds of millions of dollars. For Humana, the move covers far more than a rounding error. The upgrade impacts roughly 2.4 million members and enables Humana to qualify for bonus payments, potentially improving its profit margins and financial flexibility.
The Earnings Recovery Math
Wall Street is now recalibrating around this development fast. Baird upgraded Humana to Outperform from Neutral and raised its price target to $596 from $390, projecting Humana can achieve adjusted earnings per share of more than $35 in 2028. Cantor Fitzgerald moved the same direction before the ratings even dropped, upgrading Humana to Overweight from Neutral and raising its earnings per share estimates to $17.96 for 2027 and $28.27 for 2028. Humana’s own investor day roadmap had outlined a path to roughly $40 in adjusted EPS by 2028. The upgrade reflects conservative benefits and bids, improved stars performance, and expected deceleration in national Medicare Advantage cost trends, elements that support a path for individual Medicare Advantage margins to expand from roughly breakeven currently to more than 3% in 2028.
None of this is free money, though. The newly published ratings will primarily affect payments in 2028, and Humana’s stock had already rebounded sharply ahead of Thursday’s release. Between March and July 2026, shares more than doubled off their lows as investors priced in exactly this recovery. A 13% single-session surge on confirmation still leaves open the question of whether the full $9 of H5216-related EPS is already embedded in the price.
The Other Side of the Ledger
While Humana gained, the night’s losers were sharp. CMS cut Alignment Healthcare’s key California HMO contract H3815 to 3.5 stars from 4.0, affecting about 75% of its membership, and the stock fell more than 20% after hours. Alignment has said it expects no revenue impact for fiscal 2026 or 2027, with financial implications deferred to 2028 through the loss of quality bonus payments associated with higher star ratings. Across the broader program, approximately 71% of Medicare Advantage prescription drug enrollees are currently in contracts rated four stars or higher for 2027, with 15 MA-PD contracts earning five stars, down from 22 in 2026.
What to Watch Now
Three things will determine whether Thursday’s move holds. First, Humana’s benefit ratio: the company’s insurance segment was running near breakeven through mid-2026, and star recovery only matters if medical cost trends cooperate. Second, membership: Humana told investors in July 2026 that it expects to exit Medicare Advantage plans affecting roughly 600,000 members for the 2027 plan year. A smaller base dilutes the absolute dollar value of the bonus recovery. Third, the next ratings cycle. The four-star recovery allows Humana to continue its margin recovery and provide financial flexibility to rebuild profitability, but the company now has to hold the rating for 2028 to convert the 2027 result into lasting earnings power.
The thesis has been validated. Whether the stock price has already consumed the reward is the harder question, and the answer depends entirely on which EPS number analysts and investors choose to anchor on going into 2028.
